FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.
What happened
FDA inspected the facility from June 16 to 24, 2021, and reviewed the firm’s June 28, 2021 response to the Form FDA 483 (inspection findings). FDA found pi yen chin eye drops were made as non-sterile in a Grade D area without validated sterilization, sterility testing, or particulate testing before U.S. distribution, plus stability, out-of-specification investigation, and cleaning failures. FDA also found pi yen chin was an unapproved new drug and misbranded.
What FDA found
The firm lacked adequate written procedures and validation to prevent microbial contamination of an eye product labeled for ophthalmic use, and it released U.S. batches without sterility or particulate testing.
21 CFR 211.113(b)The firm had no written stability program or data to show pi yen chin would remain acceptable through its labeled three-year expiry.
21 CFR 211.166(a)The firm did not investigate an active ingredient infrared spectrum mismatch or unknown peaks in finished product batches, including a batch distributed to the U.S.
21 CFR 211.192Cleaning validation was inadequate, non-sterile reusable wipes were used, and rust and a fraying conveyor belt were found on product-contact equipment.
21 CFR 211.67(a)Pi yen chin is an unapproved new drug because it contains naphazoline HCl 0.1%, above the 0.01% to 0.03% allowed in the OTC ophthalmic monograph, and has no FDA-approved application.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded because the label lacks a complete U.S. address or phone number for serious adverse event reports and does not comply with section 505G marketing requirements.
FD&C Act sections 502(x) and 502(ee), 21 U.S.C. 352(x) and 352(ee)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions or a delay schedule. It also asks the firm to clarify whether it will resume U.S. drug manufacturing and to notify FDA before resuming.
Who should pay attention
- U.S. distributors and retailers that sold or stocked pi yen chin eye drops
- companies using Hubei Kangzheng as a contract manufacturer or supplier
- quality teams managing ophthalmic OTC drug suppliers
This is a summary. Read the original letter on fda.gov.